title: Prostate cancer: Validating early PSA response to enable improved treatment decisions.
authors.forename: Clemens
authors.initials: C
authors.lastname: Thoma
mesh_terms: D000069501:Abiraterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077143:Docetaxel; D016903:Drug Monitoring / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012042:Registries; D013223:Statistics as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate